Therapy for Severe Vasculitis Shows Long-Term Effectiveness

Visit us on the Web Follow us on Twitter Visit us on Facebook Follow us on LinkedIn Therapy for Severe Vasculitis Shows Long-Term Effectiveness Results from an NIAID-supported clinical trial show that administering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with severe forms of vasculitis. Rituximab’s shorter treatment duration may decrease the risk of long-term side effects of immunosuppression, such as cancer, infertility, and infection. The trial tested rituximab’s safety and effectiveness in 197 participants with the rare autoimmune diseases granulomatosis with polyangiitis, formerly known as Wegener’s granulomatosis, and microscopic polyangiitis. The researchers describe their results in the August 1 issue of the New England Journal of Medicine. Read more about the study. Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@govdelivery.com. This service is provided to you at no charge by the National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to buzzhairs.health@blogger.com using GovDelivery, on behalf of: National Institute of Allergy and Infectious Diseases · 6610 Rockledge Drive · Bethesda, MD 20892 · 866-284-4107